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Abstract
Introduction: cognitive deterioration and reductions of bone health coincide with increasing age. We examine the relation-
ship between bone composition and plasma markers of bone remodelling with measures of cognitive performance in
healthy adults.
Methods: this cross-sectional study included 225 old (52% women, mean age: 74.4 ± 3.3 years) and 134 young (52% women,
mean age: 23.4 ± 2.7 years) adult participants from the MyoAge project. Whole body bone mineral density was measured by dual-
energy X-ray absorptiometry. Blood analyses included a panel of bone-related peptides (dickkopf-1, osteoprotegerin, osteocalcin
(OC), osteopontin, sclerostin, parathyroid hormone and ﬁbroblast growth factor 23), as well as serum calcium and 25-hydroxy
vitamin D assays. A selection of cognitive domains (working memory capacity, episodic memory, executive functioning and
global cognition) was assessed with a standardised neuropsychological test battery.
Results: adjusting for covariates and multiple testing revealed that plasma OC levels were positively associated with mea-
sures of executive functioning (β = 0.444, P < 0.001) and global cognition (β = 0.381, P = 0.001) in the older women.
Discussion: these correlative results demonstrate a positive association between OC, a factor known to regulate bone
remodelling, with cognitive performance in older non-demented women. Further work should address possible mechanistic
interpretations in humans.
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Introduction
Cognitive deterioration, including the consequence of
neurodegenerative diseases, and reductions of bone health
are increasingly evident in older age. Studies have shown
relationships between measures of overall bone mineral
density (BMD) and the risks of Alzheimer’s disease and
cognitive decline especially in older women [1, 2]. This
raises the possibility that factors related to bone regulation
and function may inﬂuence cognitive performance.
Bone is a metabolically active tissue and is constantly
being remodelled throughout life mainly through the activity
of opposing specialised osteoclast and osteoblast cells via
secretory peptides and metabolites [3]. For example, differen-
tiated osteoblasts modify and deposit the non-collagenous
protein osteocalcin (OC) which, together with minerals,
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establishes the bone matrix. Conversely, the activation of
Dickkopf-1 (DKK1) can instigate osteoclast activation result-
ing in bone resorption [4].
Since many of these bone-related peptides are secreted
into the circulation, there has been growing interest into their
inﬂuences on the central nervous system [5]. For example,
Wnt signalling transduction regulates bone formation, which
is prevented through DKK1. This action has been associated
with neurodegeneration in Alzheimer’s disease [6], whereas
the loss of DKK1 has been shown to enhance neurogenesis
in mice [7]. Remarkably, bone-derived OC has been shown
to cross the blood–brain barrier and inﬂuence brain develop-
ment, cognition and behaviour in mice [8]. A recent human
study found a link between lower serum OC levels with
microstructural changes and lower cognitive performance,
which suggests that these potential neuromodulator mechan-
isms may also be present in humans [9]. Collectively, these
ﬁndings suggest that there may be a convergence in mechan-
isms underlying bone with neurodegeneration and that bone
may possess endocrine properties which aid in maintaining
cognitive wellbeing.
The majority of observational studies have focussed on
BMD measures to characterise bone health [1, 10] and question-
naires for cognitive analysis [10], which provide little mechanistic
insight and, in the case of questionnaires, lack sensitivity. Studying
biochemical markers of bone remodelling may be a more sensi-
tive analytical approach than radiological BMD measurements to
detect subtle preclinical alterations of bone metabolism. For
example, Kahl et al. [11], investigated various types of depression
in women and found elevations of serum markers of bone turn-
over associated with a relatively mild form of depression, whereas
only those with a severe depressed phenotype had reductions in
BMD.
Importantly, previous studies have focused on those
with clinically-diagnosed neurodegeneration or osteoporosis
in the elderly with very few investigating cognitively intact
and physiologically healthy subjects. Additionally, since
bone remodelling is inﬂuenced by ageing and sex, it is also
topical to investigate these independently.
This current study evaluated the relationship between
BMD and peptides associated with bone remodelling in
healthy young and older adults with measures of cognitive
performance; speciﬁcally working memory capacity, episodic
memory, executive functioning and overall performance.
Methods
Participants
MyoAge is a cross-sectional European multi-centre study
and the measurements completed in this particular study
were collected from centers located in Manchester, UK;
Paris, France; Leiden, The Netherlands; Tartu, Estonia and
Jyväskylä, Finland. The cohort consisted of young (range:
18–30 years) and relatively healthy older (range: 69–81 years)
participants. Those who completed all of the cognitive assess-
ments and had matching plasma samples available (young men,
n = 64; young women, n = 70; old men, n = 109; old women,
n = 116) were used in this study. A detailed description of the
exclusion criteria, designed to ensure the selection of healthy
participants and to minimise the confounding effect of
comorbidity on sarcopenia, has been reported previously [12].
All measurements were performed according to uniﬁed stand-
ard operating procedures during visits to the local study labora-
tories. Education levels and lifestyle factors (smoking status,
alcohol intake and supplement use) were self-reported.
Excessive alcohol was deﬁned as men >21 units/week and
women >14 units/week. Supplement usage includes those who
reported the use of bisphosphonates, calcium or vitamin D.
The local medical ethical committees of the respective institu-
tions approved the study and written informed consent was
obtained from all participants.
Dual-energy X-ray absorptiometry
Whole body scans were performed using dual-energy X-ray
absorptiometry (DXA) (The Netherlands: Hologic QDR
4500, version 12.4, Hologic Inc., Bedford, MA, USA; Finland:
Lunar Prodigy, version enCore 9.30; Estonia: Lunar Prodigy
Advanced, version enCore 10.51.006; France: Lunar Prodigy, ver-
sion enCore 12.30; United Kingdom: Lunar Prodigy Advance,
version enCore 10.50.086) to measure whole body BMD. During
the measurements, a light cotton shirt was worn by the partici-
pants to reduce effects of clothing absorption.
Cognitive assessments
Participants completed the Geriatric Depression Scale (GDS)
[13] and the Mini Mental State Examination (MMSE) [14]
questionnaires prior to testing to determine their depressive
mood and cognitive dysfunction, respectively. Only those
who achieved less than 5 points on the GDS and greater
than 23 points on the MMSE were included.
Cognitive domains were assessed using the Cambridge
Neuropsychological Test Automated Battery (CANTAB)
system (Cambridge Cognition Ltd., UK) in a quiet room
free from distractions and overseen by trained experimental
staff. The CANTAB system contains standardised assess-
ments that are routinely used in psychological assessment
[15]. Each participant performed three tests; Spatial Span,
One Touch Stockings of Cambridge and Paired Associate
Learning to determine their working memory capacity [16],
executive functioning [17] and episodic memory [18] per-
formance, respectively. Each test is discussed in detail in
Appendix 1 in the supplementary data on the journal web-
site (http://www.ageing.oxfordjournals.org/).
To standardise performances, each cognitive score was
transformed into a Z-score based on the young average. A
positive score indicates a higher than average performance,
relative to the young. The scale in episodic memory score
was inverted so a positive score will indicate a better score and
vice versa. Additionally, a global cognition score was determined
as the sum of the three individual outcomes to represent a com-
bined performance as utilised previously [19].
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Multiplex immunoassays
Peptides frequently associated with bone metabolism were
simultaneously quantiﬁed from fasted plasma samples via
commercial multiplex immunoassays (MILLIPLEX MAP
Human Bone Magnetic Bead Panel, Millipore). The magnetic
bead panel was able to simultaneously quantify, Dickkopf-1
(DKK1), osteoprotegerin (OPG), osteocalcin (OC), osteopontin
(OPN), sclerostin (SOST), parathyroid hormone (PTH) in a 96-
well format. The procedure included an overnight incubation in
order to improve assay sensitivity. The sensitivity of each analyte
was as follows: 1.4 (DKK1), 1.9 (OPG), 68.5 (OC), 37.7
(OPN), 31.1 (SOST), 1.8 (PTH) and 9.2 (FGF-23) pg/ml. A
magnetic plate washer was utilised during the plate washing
stages. The plate was processed on a Luminex 200 instrument.
Protein concentrations were calculated and analysed with the
xPONENT software (Luminex, v.3.1.871).
Serum calcium and 25-hydroxy vitamin D
Serum samples were tested for calcium using a calcium CP
reagent on a Horiba ABX Pentra 400 Clinical Chemistry analyser.
Serum 25-hydroxy vitamin D (25(OH)D) was determined using
an enzyme linked immunosorbent assay (Immunodiagnostic
Systems Ltd) according to the manufacturer’s instructions.
Analysis was conducted at Unilever Discover, Colworth
Science Park.
Statistics
All statistical analysis was performed using IBM SPSS
Statistics software (v.20). Results were deemed signiﬁcant at
the P < 0.05 level, unless otherwise stated. Logarithmic
transformation was performed on plasma bone marker data
to achieve normality. Continuous data were tested using
two-way ANOVA to determine possible age (young or old),
sex (men or women) effects and age×sex interactions.
Pearson chi-squared tests were performed to determine
distribution differences between nominal data. Mann–
Whitney U tests were performed to determine differences in
cognitive performance between age groups.
To determine plasma bone marker relationship with the
measures of cognitive functioning, Spearman correlation
analysis was initially performed followed by multivariate
regression. Factors identiﬁed as being signiﬁcantly associated with
cognitive function were investigated further to account for con-
founders through separate multivariate regression models. Scores
of cognitive functioning were set as the dependent variable and
the bone markers, as well as potential confounders, were set as
the independent variables. To identify confounders, correlations
between cognitive scores and physiological measures (height,
body mass, body mass index (BMI), BMD, serum calcium and
25(OH)D) were used. A confounder was identiﬁed if a relation-
ship existed at the P < 0.1 level, as used previously [20].
Following this analysis, BMD, BMI, height and 25(OH)D were
all selected as possible confounders to be included in ﬁrst
regression model, along with age, education level and participant
location. A second model was also used, which contained
Model 1 as well as lifestyle factors (current smoking status,
excessive alcohol use and supplement use). The residuals of
both regression models were normally distributed as assessed
by the Durbin-Watson statistic. Due to multiple testing
(four tests), a Bonferroni corrected level of signiﬁcance of
P < 0.0125 (0.05/4) was applied for this analysis.
Results
Participant characteristics are presented in Table 1.
As expected, the younger participants performed signiﬁ-
cantly better on each cognitive test compared with older
adults (Figure 1). Men had a better working memory capacity in
the older group when compared with women (men median:
−1.97; IQR: −1.97 to −1.14; women median: −1.97; IQR:
−1.97 to −1.97; P = 0.017). No signiﬁcant differences in
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 1. Participant characteristics, stratiﬁed by physiological, lifestyle and education parameters
Variables Young Old Effects (P-value)
Men Women Men Women Age Sex Age × Sex
Age, years 23.74 (2.67) 23.05 (2.77) 74.75 (3.35) 74.16 (3.34) <0.001* 0.063 0.878
Height, m 1.81 (0.06) 1.68 (0.06) 1.74 (0.06) 1.61 (0.07) <0.001* <0.001* 0.791
Body mass, kg 75.41 (10.30) 62.90 (9.04) 78.26 (11.10) 65.92 (10.10) 0.009* <0.001* 0.940
BMI, kg/m2 23.03 (2.66) 22.27 (2.85) 25.71 (2.96) 25.37 (3.63) <0.001* 0.103 0.540
BMD, g/cm2 1.26 (0.10) 1.15 (0.07) 1.19 (0.11) 1.04 (0.10) <0.001* <0.001* 0.074
Current smoker, n (%) 6 (9.4) 8 (11.4) 7 (6.4) 4 (3.4) 0.045* 0.693 0.173
Excessive alcohol use, n (%) 10 (15.6) 5 (7.1) 12 (11) 7 (6) 0.389 0.043* 0.160
Supplement intake, n (%) 4 (6.3) 1 (1.4) 14 (12.8) 36 (31) <0.001* 0.013* <0.001*
Education, n (%)a
Basic school 0 (0) 0 (0) 13 (15.3) 17 (17.9) <0.001* 0.083 <0.001*
High school 9 (16.4) 5 (8.6) 22 (25.9) 45 (47.4)
University 46 (83.6) 53 (91.4) 50 (58.8) 33 (34.7)
MMSE score, median (IQR) 30 (29–30) 30 (29–30) 29 (28–30) 29 (28–30) <0.001* 0.594 0.508
GDS score, median (IQR) 0 (0–1) 0 (0–1) 1 (0–2) 1 (0–2) 0.002* 0.544 0.356
BMI, body mass index; BMD, bone mineral density; MMSE, Mini Mental State Examination; IQR, interquartile range; GDS, Geriatric Depression Scale. Data are
shown as mean (standard deviation), unless otherwise stated. * indicates a signiﬁcant (P < 0.05) effect or interaction.
aData available in: young men n = 55; young women n = 58; old men n = 85; old women n = 95.
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episodic memory, executive functioning and global cognition
were seen between sexes in either young or old groups.
Blood concentrations of the bone-related markers, as
well as serum calcium and vitamin D, signiﬁcantly differed
by both age and sex groups. Refer to Appendix 2 in the
supplementary data on the journal website (http://www.
ageing.oxfordjournals.org/) for the full analysis.
There were no signiﬁcant associations observed between
whole body BMD with episodic memory, working memory,
executive functioning or global cognition in young women,
young men, old women or old men (data not shown).
Furthermore, investigations into serum 25(OH)D and calcium
were not signiﬁcantly associated with any of the measures of
cognitive functioning (data not shown).
Initial exploratory analysis between the four measures of
cognitive scores and seven plasma markers revealed some
sex- and age-speciﬁc associations (Table 2). There was no
relationship found in the men. There was a negative association
between overall cognitive scores and DKK1 in the young
women. The old women had a positive association between
OC and working memory capacity, executive functioning and
global cognition scores.
Those signiﬁcant relationships were analysed further to
account for potentially confounding effects of other variables.
After adjusting for participant age, country, education level the
confounding variables previously highlighted in the preliminary
analysis (Model 1) the relationship between DKK1 and global
cognition in the young women was no longer signiﬁcant
(Table 3). Despite the association of OC with working mem-
ory capacity in the old women, this failed to reach the
Bonferroni corrected threshold (P > 0.0125). After Model 1
adjustments, signiﬁcance remained for OC with executive
functioning and global cognition in old women even after
accounting for multiple comparisons (Table 3). Independently,
OC was a signiﬁcant predictor of executive functioning
(F(1,114) = 5.668; P = 0.019; R
2 = 0.047) and global cognition
(F(1,114) = 4.164; P = 0.044; R
2 = 0.035) in older women.
A second model (Model 2) was also used, which
included the variables in Model 1 as well as supplement
intake, current smoking status and excessive alcohol
use, which have previously been linked to cognitive decline
in the elderly [19]. The relationships between OC with
executive functioning and global cognition in old women
remained after the adjustment with this model (Table 3).
Discussion
In the present investigation, we identiﬁed a relationship
between OC and multiple measures of cognitive performance
in old women.
Figure 1. Cognitive performance in the two age groups. Data
are shown as median, interquartile range and minimum and
maximum. Z scores are relative to the young group’s average
value for each cognitive output. ***P < 0.001.
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Table 2. Correlation between cogntive measures and plasma bone markers
Variable DKK1 OPG OC OPN SOST PTH FGF-23a
Young men
Working memory capacity −0.069 −0.139 0.115 −0.127 0.061 0.027 −0.063
Episodic memory 0.065 0.237 0.078 0.050 0.078 0.181 −0.118
Executive functioning −0.026 −0.012 −0.018 −0.068 −0.092 0.069 −0.011
Global cognition −0.034 −0.063 0.042 −0.144 0.002 0.063 −0.077
Young women
Working memory capacity −0.208 0.217 −0.173 0.059 −0.149 0.188 0.168
Episodic memory −0.226 −0.121 0.068 −0.234 0.080 −0.026 0.234
Executive functioning −0.092 −0.124 0.090 −0.036 −0.057 0.076 −0.040
Global cognition −0.287* 0.049 −0.069 −0.067 −0.144 0.163 0.095
Old men
Working memory capacity −0.094 −0.155 −0.118 0.037 −0.115 0.015 0.109
Episodic memory −0.041 −0.035 −0.102 −0.022 −0.040 0.071 0.039
Executive functioning −0.017 0.184 0.050 0.050 0.046 0.000 −0.105
Global cognition −0.062 0.016 −0.092 −0.023 −0.037 0.037 −0.044
Old women
Working memory capacity 0.085 0.053 0.256** 0.178 0.117 0.150 −0.145
Episodic memory −0.101 −0.150 0.147 0.114 −0.030 0.008 −0.021
Executive functioning −0.127 −0.077 0.252** 0.111 −0.041 −0.002 0.097
Global cognition −0.107 −0.092 0.245** 0.156 −0.004 0.025 0.031
DKK1, Dickkopf-1; OPG, osteoprotegerin; OC, osteocalcin; OPN, osteopontin; SOST, sclerostin; PTH, parathyroid hormone. Data are shown as Spearman cor-
relation coefﬁcient (rho). *P < 0.05. **P < 0.01.
aSome samples were below the lower limit of detection for FGF-23. Data available in: young men, n = 46; young women, n = 58; old men, n = 78; old women,
n = 87.
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Comparing cognitive performances between ages indicated
that the old had lower working memory capacity, executive
functioning capability and episodic memory compared with the
young adults. Reductions of most cognitive domains have been
noted including memory (episodic, working and verbal), spatial
visualisation, processing speed and reasoning [21]. The cause
of this phenomenon is yet to be fully elucidated, however, a
multifactorial origin is likely to explain this age-related cognitive
decline. Additionally, the ﬁnding of men having a higher work-
ing memory capacity than women is consistent with previous
reports [21], which suggests that sex is a determining factor in
certain cognitive performances.
When correlating BMD with cognition in the young and
older adults we found no associations. Previous structural
analysis of bone health with neuropsychological functioning
has suggested that lower BMD is associated with lower cog-
nitive performance, particularly in post-menopausal women
[2, 10]. Additionally, incidence of Alzheimer’s disease is
believed to be higher in those with low BMD [1]. These
previous studies that associated clinically-diagnosed poor
cognition with low BMD contrast with the present ﬁndings
in healthy older people and it is possible that the association
only becomes evident at the later stages of the physiological
declines. Analysis of vitamin D and calcium serum levels
with relation to cognitive scores suggested no association in
the older adults. Despite vitamin D levels being marginally
reduced in the older adults reported here, they were still
within the optimal reference range (25–80 ng/ml) [22], which
may explain the lack of associations in our elderly groups.
Multiple cognitive measures were positively associated
with plasma OC levels in older women even after adjusting
for confounders in multivariate regression analysis. OC,
secreted by osteoblasts, is often used as a marker of bone
formation [23] and has been shown to possess endocrine
properties such as glucose metabolism [24]. Interestingly,
Oury et al. [8] demonstrated that bone-derived OC can passively
cross the blood–brain barrier, as well as the placenta during
pregnancy, to inﬂuence neurons in various brain regions
including the hippocampus. Speciﬁcally, these investigators noted
that OC enhanced neurotransmitter synthesis, neurogenesis and
measures of spatial learning and memory in mice [8].
From a human clinical perspective, mutations in the
RUNX2 gene, the main regulator of OC [25], are known to
cause Cleidocranial dysplasia that often presents with cognitive
impairments [26]. Furthermore, a recent study on obese and
control human subjects found that lower OC was associated
with higher BMI and lower cognitive performance together
with brain microstructural changes [9]. The authors calculated
that serum OC independently explained 10% of the variation
in cognitive performance [9]. In this study, we found that
plasma OC solely predicted global cognition and executive
functioning by 3.5 and 4.7%, respectively. These relatively
small effect sizes imply that OC is not the sole mediator in
cognitive functioning, which is to be expected considering
the complex multifactorial nature of cognitive functioning.
Nevertheless, the aforementioned mechanisms linking OC
with neuro-modulatory functions in mice [8] and the correla-
tions between numerous cognitive measures in humans, as
presented here and elsewhere [9], warrant the need to
explore this bone-related peptide further to establish a causal
relationship with neuromodulation.
The present study has a number of strengths, particularly
with respect to the younger and older cohorts carefully selected
to ensure they were healthier than average for their age and
they undertook detailed cognitive assessments. The study, how-
ever, has several limitations. The cross-sectional design limits a
deﬁnitive conclusion regarding a cause-and-effect relationship
between the plasma markers and cognitive decline, instead we
found a correlation rather than causation. We also did not
account for variations between the older women in their men-
strual status, although they were all post-menopausal, and hor-
monal inﬂuences (such as oestrogen levels) in women as well as
thyroid function. These factors may contribute to the lack of
associations in males in our analysis; however, further work is
needed to investigate this potential sexual dimorphic pattern.
Collectively, the fact that we found no associations
between whole body BMD and cognition in our population
but, instead, relationships with osteocalcin suggest that the
alterations in bone remodelling factors might precede
changes in BMD with relation to cognition. Further longitudinal
studies investigating bone remodelling proteins, particularly OC,
as well as BMD with cognitive performance in older women
are needed to elucidate the proposed relationship between bone
health and neuromodulation.
Keypoints
• We ﬁnd no associations between whole body bone min-
eral density and cognition in a relatively healthy elderly
population.
• Plasma levels of osteocalcin associate with measures of
executive functioning and cognition in older women.
• Plasma levels of bone remodelling peptides associate with
measures of executive functioning and cognition in older
women.
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
Table 3. Multivariate regression analysis of bone markers
with cognitive functioning
Relationships Model 1 Model 2
β P-value β P-value
Young women
Global cognition and DKK1 −0.301 0.079 −0.243 0.158
Old women
Working memory capacity and OC 0.291 0.014 0.274 0.018
Executive functioning and OC 0.433 <0.001* 0.444 <0.001*
Global cognition and OC 0.369 0.001* 0.381 0.001*
β, standardised coefﬁcient; BMI, body mass index; DKK1, Dickkopf-1; OC,
osteocalcin. Model 1 included adjustments for age, participant country, educa-
tion level and those factors which were discovered in the preliminary analysis
(whole body BMD, BMI, height, 25(OH)D). Model 2 included Model 1 and life-
style factors (current smoking status, excessive alcohol use and supplement use).
*Correlation remained signiﬁcant after accounting for multiple testing via the
Bonferroni correction method (P < 0.0125).
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